Windward Bio Raises $165M in Upsized Crossover Round to Advance Long-Acting Immunology Pipeline

New updates have been reported about Windward Bio.

Windward Bio has secured an upsized $165 million crossover financing led by OrbiMed, bringing total capital raised since its January 2025 launch to $365 million and materially extending its cash runway to support multiple near-term clinical readouts. The round, which significantly broadens the company’s investor base with RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed joining existing backers such as Novo Holdings and Blue Owl Healthcare Opportunities, is designed to fund pivotal development of its two lead immunology programs.

Proceeds will primarily accelerate WIN378, an ultra long-acting, fully human anti-TSLP monoclonal antibody positioned to be a first-to-market, twice-yearly biologic in asthma and other immunological diseases, now in the Phase 2/3 POLARIS asthma program with initial data expected in the second half of 2026 and a first Phase 3 trial slated for the fourth quarter of 2026. Windward will also use the capital to initiate a Phase 2 COPD trial for WIN378 in the second quarter of 2026 and to advance WIN027, a long-acting bispecific targeting TSLP and IL‑13 licensed from Qyuns Therapeutics, which is in Phase 1 with data expected by year-end 2026 and will support multiple respiratory and dermatology proof‑of‑concept studies starting in the fourth quarter of 2026.